|
SRD5A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.24199580911977E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.61870003249021E-09 |
| Normal-vs-Stage2 |
1.359800E-01 |
| Normal-vs-Stage3 |
2.20480000001633E-06 |
| Normal-vs-Stage4 |
2.00909999999999E-05 |
| Stage1-vs-Stage2 |
6.096100E-02 |
| Stage1-vs-Stage3 |
2.589600E-01 |
| Stage1-vs-Stage4 |
6.224400E-02 |
| Stage2-vs-Stage3 |
2.296400E-02 |
| Stage2-vs-Stage4 |
6.678900E-03 |
| Stage3-vs-Stage4 |
3.633000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.65899976983997E-10 |
| Normal-vs-AfricanAmerican |
1.817540E-03 |
| Normal-vs-Asian |
2.37629999999545E-06 |
| Caucasian-vs-AfricanAmerican |
8.576800E-01 |
| Caucasian-vs-Asian |
8.399800E-01 |
| AfricanAmerican-vs-Asian |
7.651000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.68880000381589E-08 |
| Normal-vs-Female |
1.623900014458E-09 |
| Male-vs-Female |
5.664600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.03979996729709E-09 |
| Normal-vs-Age(41-60Yrs) |
1.06560000001643E-06 |
| Normal-vs-Age(61-80Yrs) |
2.161800E-04 |
| Normal-vs-Age(81-100Yrs) |
5.690100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.538000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.854600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.801600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.117400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.477200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.000800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.642400E-02 |
| Classical-VS-Follicular |
7.36750000007724E-07 |
| Classical-VS-Other |
4.432600E-01 |
| Classical-VS-Normal |
1.35647049148702E-12 |
| Tall-VS-Follicular |
9.57590000000286E-05 |
| Tall-VS-Other |
6.240000E-01 |
| Tall-VS-Normal |
2.26449999999323E-05 |
| Follicular-VS-Other |
1.439920E-02 |
| Follicular-VS-Normal |
5.115400E-01 |
| Other-VS-Normal |
5.135700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.155000E-04 |
| Normal-vs-N1 |
1.255230E-03 |
| N0-vs-N1 |
5.406300E-02 |
|
|
